# Lane B round 3 - STAGED 2026-09-26 ~21:26 IST (browser cap; fire when slot passed after midnight)
# Fill {{GATE_OUTCOMES}} with live Phase-2 numbers before sending. Two branches: PASS-branch and FAIL-branch questions. Paste as ~3 messages under 4k chars each.

MESSAGE 1:
Judge round 3 for MorphoScan. Round 1 you redirected me to frozen CTransPath embeddings + pathway-level prediction. Round 2 you reviewed the locked PREREG-2 pre-run (8.8/10, "proceed, do not redesign") and I adopted 7 of your 8 fixes before the run: tile physical scale locked (~150um spot-centered tiles on the 200um-pitch HER2-ST platform, no neighbor centers), Hallmark membership frozen with download date, numeric shuffle-null threshold (|r|<0.02 within 95% CI), D1 split confirmatory/exploratory, external cohort frozen (10x Parent_Visium_Human_BreastCancer), D2 rewritten as morphology-defined molecular niches (embedding clusters, per-cluster pathway states, Moran's I vs shuffled-coordinate null), and a scoped HistGradientBoosting baseline on the 49 pathway targets. The one fix I rejected was downgrading G2-B from pass/fail - the preregistration is locked and I do not edit gates after locking; the caveat is pre-committed in the round log.

The Phase-2 run is complete. Here are the locked-gate outcomes, live-verified.

MESSAGE 2 (numbers):
{{GATE_OUTCOMES}}

Gates recap: G2-R median held-out per-gene Pearson >=0.08 AND beats Phase-1 handcrafted in >=80% of 250 genes (Wilcoxon p<0.05). G2-P median pathway Pearson >=0.20, permutation p<0.01, immune-program AUROC >=0.75. G2-B vs ST-Net 0.19 (match/beat; logged honestly either way). G2-X external frozen-model pathway Pearson >=0.10. G2-A shuffled controls at numeric chance. G2-S scanner patient-held-out AUC >=0.85. D1 >=50 held-out genes at Pearson >=0.15 with pathway enrichment. D2 non-random spatial pathway architecture.

MESSAGE 3 (questions - keep the branch that applies, delete the other):
PASS-branch:
1. Which result is the strongest headline for a judge, and what is the sharpest skeptical attack on it I should pre-empt in the paper?
2. For the molecular-niche discovery: what validation would make "morphology-defined molecular niches" a discovery rather than a clustering exercise? Rank 3 cheap validations.
3. What does this project still lack to be unforgettable: (a) a second external cohort, (b) a clinical-outcome link, (c) an interactive tool, (d) something else?
FAIL-branch (per rule: stalled negative -> ask for redirection):
1. Which failed gate is the real scientific signal and which is an execution artifact? Be specific about what evidence distinguishes them.
2. Given the locked pivot ladder (spatial-graph aggregation, multi-scale tiles, UNI/CONCH representation), which rung do I climb and why?
3. Is there a redirection I am not seeing that this exact data (68 sections, embeddings, 250 genes, 49 pathways) can support within days, not weeks?
